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Age-related macular degeneration (AMD) continues to be amongst the leading causes of blindness and visual
impairment worldwide. AMD remains a degenerative disorder of unknown etiology with rising prevalence. It
induces retinal changes and damages those parts of the retina which are essential for central vision. The risk of
developing this condition is associated with increasing age. Early stages usually progress without warning signs
over years. The major identified risk factors for AMD development are age, ethnicity, family history, and current
smoking. Associations of other modifiable risk factors with AMD have been widely published but these studies have
reported conflicting results and showed a lack of consistency. According to recent data published in BMC Medicine
from the population-based Rotterdam study, thyroid hormones may contribute to a better characterization of AMD
in clinical practice. In that study serum free thyroxine levels were positively associated with development of AMD.
More studies are needed to validate these findings and to understand better the role of thyroid hormones in the
pathogenesis of AMD disease.
Please see related article: http://dx.doi.org/10.1186/s12916-015-0329-0
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In 1990 and 2010, age-related macular degeneration
(AMD) was amongst the leading causes of blindness and
visual impairment worldwide [1]. The greatest preva-
lence was reported in developed countries, especially in
high-income regions. Such regions face the strongest
demographic shift where overaging societies increase the
prevalence of age related diseases in general. In the
United States the number of persons affected by AMD
was estimated to increase by 50% until 2020, based on
population demographics [2]. The visual impairment
caused by AMD presents a tremendous economic bur-
den and major limitations in quality of life [3,4].
Pathophysiology and clinical aspects of AMD
AMD increases strongly with age and is characterized by
the presence of drusen or pseudodrusen, abnormalities
in retinal pigmentation, geographic atrophy, neovascu-
larization, or angiomatous proliferation. Drusen are
small white or yellowish extracellular deposits in the* Correspondence: till.ittermann@uni-greifswald.de
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article, unless otherwise stated.retina. They are located between the retinal pigment epi-
thelium (RPE) and the Bruch’s membrane. A number of
grading schemes has been developed based on the size
and number of drusen and the amount of other retinal
lesions. A common classification was defined by the
Age-Related Eye Disease Study (AREDS) [5], which sub-
divides AMD into the categories no AMD, early AMD,
intermediate AMD, and advanced AMD. These stages
represent the natural history of AMD, which gener-
ally progresses from the ‘dry’ (atrophic) to the ‘wet’
(neovascular) form. It is clinically important that early
stages may persist over many years without any signs or
discomfort. The typical AMD patient is over 55 years old
and often presents with neovascular conditions as the
first manifestation. This can be explained by the fact that
pathogenic mechanisms of AMD development and pro-
gression remain poorly understood. For this reason, there
is no causative therapy available. Instead, the rationale
for treatment is to prevent vision loss by delaying onset
or progression to later stages, and by reducing neovascu-
larization [6]. Treatment modalities have to be adapted
to their respective stages, whereas no benefit of thera-
peutic interventions has been published for early AMD.d Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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might be attenuated by a daily antioxidant therapy. In
2001 the AREDS group reported a reduced odds ratio of
0.72 in the antioxidants group [5]. The introduction
of substances that inhibit vascular endothelial growth
factors (VEGF) led to more effective treatments of
neovascularization. Consequently, intravitreal injection of
anti-VEGF drugs has become primary therapy for most
cases of advanced AMD [7]. The repeated application of
these substances obtains beneficial therapeutic effects in
the macular region resulting in good visual restoration.
Potential systemic side effects of these agents aroused
concerns about cardiovascular and hematologic compli-
cations, but the real evidence of such events is largely
unknown.
Screening and diagnostic procedures
Several diagnostic tests have been established to assess
signs of AMD. Funduscopy, optical coherence tomog-
raphy, and angiography are medical imaging procedures
used to diagnose AMD and to determine disease pro-
gression. Testing visual acuity is essential to evaluate
visual impairment. Early treatment is crucial for patients
who develop wet AMD, because it reduces the risk of
vision loss and may improve the final visual outcome.
With the introduction of new therapeutic methods, early
detection will also become increasingly important for
early AMD stages. However, screening for AMD is not
common yet. Although patients’ self-testings (that is,
Amsler grid [8]) show low sensitivity [9], best practice
guidelines recommend encouraging patients to assess
their own visual acuity [6]. Improved knowledge of risk
factors may help to develop comprehensive screening
strategies.
Risk factors
Several studies have identified age, ethnicity, and family
history (genetics) as major risk factors for the develop-
ment of wet AMD [10,11]. Smoking is also strongly as-
sociated with AMD. It appears to be the only modifiable
risk factor that has been consistently identified in the lit-
erature [12]. Smoking cessation reduces the risk of
AMD development and progression. Thus, it should be
beneficial to generate awareness about the risk of devel-
oping AMD from the toxic effects of cigarette smoking.
Associations with other modifiable risk factors have been
widely published but these studies have reported con-
flicting results and showed a lack of consistency: hyper-
tension and cardiovascular risk factors [13-20], dietary
fat intake [11,20-25], aspirin use [26,27], sunlight expos-
ure [28-30], and alcohol [31]. Thus, the pathogenesis of
AMD is currently poorly understood and it is important
to identify potential risk factors for this disease. The
work by Chaker et al. suggests that thyroid function isan important risk factor for AMD [32]. In that study,
based on data from the population-based Rotterdam
study, serum free thyroxine levels were positively associ-
ated with development of AMD. There was no associ-
ation of serum thyroid-stimulating hormone (TSH) with
this outcome.
Association between serum TSH levels and macular
degeneration within the Study of Health in Pomerania
(SHIP-Trend)
In SHIP-Trend, a population-based cross-sectional study
conducted in Northeast Germany, data from 3,070 indi-
viduals 20- to 80-years old were available to investigate
the association between serum TSH levels and macular
degeneration [33]. Serum TSH levels were measured by
an immunochemiluminescent procedure (Vista, Siemens,
Eschborn, Germany). Macular degeneration was evalu-
ated by an experienced reader based on images from
fundus photography of the central retina derived from
a non-mydriatic fundus camera (TRC-NW 200, Topcon
Corporation, Tokyo, Japan) [34]. There were 62 individ-
uals with macular degeneration in SHIP-Trend (2.0%).
In logistic regression adjusted for age, sex, smoking
status, hypertension, cholesterol, diabetes and body
mass index we found, in agreement with the findings
of Chaker et al., no significant association between
serum TSH levels and macular degeneration (odds ratio
(OR) = 0.99; 95% confidence interval (CI) = 0.92 to 1.07).
Likewise, there was no significant association between
serum TSH levels within the reference range and macular
degeneration (OR = 1.08; 95%CI: 0.63 to 1.84). Restricting
the age range to individuals ≥55 years did not change the
results significantly. Unfortunately, serum fT4 levels were
not measured in SHIP-Trend, so that we were not able to
verify the significant positive association between fT4
and macular degeneration detected in the Rotterdam
study.
Conclusions
AMD is a disease whose risk factors and pathophysi-
ology are not well understood and, thus, AMD is often
diagnosed in an already advanced stage. Thyroid hor-
mones may contribute to a better characterization of
AMD in clinical practice as shown by the data of
Chaker et al. [32].
Even though observational studies cannot determine
causal inference, they provide useful evidence to im-
prove the perception of specific illnesses. However, more
studies are needed to validate the findings of Chaker et al.
and to understand better the role of thyroid hormones in
the pathogenesis of the AMD disease.
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